替雷利珠联合仑伐替尼治疗中晚期肝癌的临床疗效分析  

Clinical efficacy of Tirellizumab combined with lenvatinib in the treatment of advanced liver cancer

作　　者：吴园园 李晨露[1] 陈燕[1] 曹梦妲 邵华[1] WU Yuanyuan;LI Chenlu;CHEN Yan;CAO Mengda;SHAO Hua(Department of Pharmacy,Zhong da Hospital of Southeast University,Nanjing 210009,Jiangsu,China)

机构地区：[1]东南大学附属中大医院药学部,江苏南京210009

出　　处：《中国临床药理学与治疗学》2025年第3期392-397,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：2022白求恩·求索-药学科研能力建设项目(Z04JKM2021005);南京市药学会-常州四药医院药学科研基金(2021YX010)。

摘　　要：目的:探讨替雷利珠单抗联合免疫检查点抑制剂仑伐替尼靶向治疗中晚期肝细胞癌(hepatocellular carcinoma,HCC)的疗效与安全性。方法:回顾性分析2021年1月至2022年12月收治于东南大学附属中大医院52例以替雷利珠单抗、仑伐替尼及两者联合治疗的中晚期HCC患者,以患者疾病进展、死亡、不可耐受不良反应为终点,按照RECIST 1.1标准进行疗效评估,随访时间截至2023年6月。主要研究终点为客观缓解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)、无进展生存期(progression-free survival,PFS)及安全性。结果:与替雷利珠单药或仑伐替尼单药组相比,两者联合治疗可显著改善患者的ORR和mPFS。与单一替雷利珠单抗或仑伐替尼给药相比,两者联合治疗相关不良反应无明显差异,提示两者联用总体耐受性良好,副作用可控。结论:替雷利珠单抗联合仑伐替尼治疗HCC疗效更好,可显著延长PFS,总体耐受性良好,可能是晚期HCC的一种潜在治疗方案。AIM:To investigate the efficacy and safety of checkpoint inhibitor lenvatinib combined with Tirelizumab in the treatment of advanced hepatocellular carcinoma(HCC).METHODS:A retrospective analysis was performed on 52 patients with advanced HCC treated with Renvatinib,tirellizumab or their combination from January 2021 to December 2022 in Zhongda Hospital Affiliated to Southeast University,with disease progression,death and intolerance as endpoints.Efficacy was assessed according to RECIST 1.1 criteria and followup was conducted up to June 2023.The main endpoints of the study were objective response rate(ORR),disease control rate(DCR),progression-free survival,(PFS)and security.RESULTS:The combination therapy significantly improved ORR and mPFS in patients compared with tirelizumab or lenvatinib monotherapy.Compared with single tirellizumab or lenvastinib,there was no significant difference in the adverse reactions associated with the combination treatment,suggesting that the combination of the two was generally well tolerated and the side effects are controllable.CONCLUSION:Lonvastinib combined with tirelizumab is more effective in the treatment of HCC,can significantly prolong PFS,and is generally well tolerated,which may be a potential treatment for advanced HCC.

关 键 词：替雷利珠单抗 仑伐替尼 免疫治疗 靶向治疗 临床疗效 

分 类 号：R735.7[医药卫生—肿瘤]